The 26S proteasome complex: An attractive target for cancer therapy
- 31 January 2012
- journal article
- review article
- Published by Elsevier BV in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Vol. 1825 (1), 64-76
- https://doi.org/10.1016/j.bbcan.2011.10.003
Abstract
No abstract availableKeywords
This publication has 148 references indexed in Scilit:
- A phase I study of bortezomib and temozolomide in patients with advanced solid tumorsCancer Chemotherapy and Pharmacology, 2011
- Distinct regulatory mechanisms of eukaryotic transcriptional activation by SAGA and TFIIDBiochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms, 2011
- Proteasome inhibitors in cancer therapyJournal of Cell Communication and Signaling, 2011
- Genome wide transcriptional profiling in breast cancer cells reveals distinct changes in hormone receptor target genes and chromatin modifying enzymes after proteasome inhibitionMolecular Carcinogenesis, 2008
- Glycogen storage disease type III-hepatocellular carcinoma a long-term complication?Journal of Hepatology, 2007
- Integrating cell-signalling pathways with NF-κB and IKK functionNature Reviews Molecular Cell Biology, 2007
- Structural Determinants Involved in the Regulation of CXCL14/BRAK Expression by the 26 S ProteasomeJournal of Molecular Biology, 2006
- Drug discovery in the ubiquitin–proteasome systemNature Reviews Drug Discovery, 2006
- Salinosporamide A: A Highly Cytotoxic Proteasome Inhibitor from a Novel Microbial Source, a Marine Bacterium of the New Genus SalinosporaAngewandte Chemie, 2003
- Structure of 20S proteasome from yeast at 2.4Å resolutionNature, 1997